Clinical Trial: Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07133802) titled 'Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination' on Aug. 14.

Brief Summary: A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Prevention of Influenza

Intervention: BIOLOGICAL: Placebo Group

Each human dose: 0.2 mL

BIOLOGICAL: Test Group

Each human dose is 0.2 mL

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Changchun BCHT Biot...